Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cilp2 in the preparation of drugs for improving cardiac aging and cardiac hypertrophy

A technology for cardiac hypertrophy and cardiac aging, applied in the field of biomedicine, can solve problems such as the lack of NPP catalytic sites, achieve the effects of reducing cardiac hypertrophy and fibrosis, improving cardiac hypertrophy, and improving cardiac aging

Active Publication Date: 2021-07-30
WUHAN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The homology of the C-terminus and nucleotide pyrophosphohydrolase (NTPPHase) is as high as 90.9%, which may be related to the activity of nucleotide pyrophosphodiesterase (NPP), but it lacks NPP catalytic sites or bivalent cation binding site

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cilp2 in the preparation of drugs for improving cardiac aging and cardiac hypertrophy
  • Application of cilp2 in the preparation of drugs for improving cardiac aging and cardiac hypertrophy
  • Application of cilp2 in the preparation of drugs for improving cardiac aging and cardiac hypertrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] In order to make the purpose of the present invention, technical solutions and advantages clearer, the present invention will be described in further detail below in conjunction with the examples, and the equipment and reagents used in each embodiment and test example can be obtained from commercial sources unless otherwise specified. The specific embodiments described here are only used to explain the present invention, not to limit the present invention.

[0027] From the information contained herein, various changes in the precise description of the invention will readily become apparent to those skilled in the art without departing from the spirit and scope of the appended claims. It should be understood that the scope of the present invention is not limited to the processes, properties or components defined, since these embodiments, as well as other descriptions, are only intended to illustrate certain aspects of the invention. In fact, various changes to the embod...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biomedicine, and particularly relates to the application of CILP2 in the preparation of drugs for improving heart aging and cardiac hypertrophy. The invention takes mice as the experimental object, uses AAV9 virus to overexpress the CILP2 gene at the transcription level, and conducts comparative research by establishing models of cardiac aging and cardiac hypertrophy. The results showed that compared with the aging wild-type control group, overexpression of CILP2 could significantly reduce the levels of aging indicators in the heart of aging mice, reduce the levels of myocardial inflammatory factor indicators in aging mice, and improve the expression levels of myocardial hypertrophy markers. The thickness is reduced, the degree of fibrosis is weakened, and the number of cardiomyocytes is reduced. The above results prove that the expression level of CILP2 can regulate the occurrence of cardiac aging and cardiac hypertrophy, and has a protective effect on cardiac aging and cardiac hypertrophy. Base.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and particularly relates to the application of CILP2 in the preparation of drugs for improving heart aging and cardiac hypertrophy. Background technique [0002] Health, aging and longevity are the most concerned issues, and people have been exploring the mysteries since ancient times. As our country enters an aging society, the diseases brought about by age increase seriously threaten human health, but the current understanding of aging is still in its infancy. Among diseases caused by aging, cardiovascular disease has topped the list of causes of death over the years, and heart failure is one of the most common causes of death. Recently, at the protein level, GDF11 and TIMP2 were identified as potential antiaging factors. The application of anti-aging factors to aging organisms can slow down the progress of organ aging, and improve the functions of heart aging and cardiac hypertrophy and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/17A61K45/00A61P9/04
CPCA61K38/1709A61K45/00A61P9/04
Inventor 王志华汤立许李丽莉罗强胡依萌
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com